OREANDA-NEWS. The latest edition of research, the Bayer scientific magazine, showcases current topics in medical and agricultural research. In the cover story “Fitness strategy for wheat, soybeans and other crops”, plant experts from Bayer explain how they are decoding plant life in minute detail, yielding valuable knowledge for new breeds and innovative crop protection products and thus helping crops withstand the most unfavorable of conditions. When exposed to stress, plant cells switch to emergency mode, putting the harvest at risk. The scientists help cereals and other crops cope better with their environment and deliver good harvests.

Bayer’s scientists in Oslo explain how radioactivity could be used to fight cancer: they are developing a new drug product that is designed to selectively find its way through the body to tumors and then release alpha radiation locally. It is intended to be used primarily to treat refractory tumors that no longer respond to chemotherapy. The novel radioimmunotherapy approach could be a source of new hope for patients with lymph node, prostate or breast cancer.

The magazine also turns its attention to a special kind of stem cell: using induced pluripotent stem cells derived from skin tissue, Bayer researchers can simulate organs and even diseases in the petri dish. As such, these cells have great potential in drug research.

Bayer's science magazine features stories researched using journalistic criteria and selected to illustrate how research can improve the lives of humans, animals and plants – fully in keeping with the company's mission, "Bayer: Science For A Better Life". The texts are designed to appeal to the reader with explanatory illustrations, attractive photo galleries showing life in the laboratory and out in the field, and interviews with renowned international scientists. They make the approaches and technologies being used today even more accessible.

The online edition of research: bringing science to life
Bayer's science magazine research is also available online. Go to www.research.bayer.com and immerse yourself in the world of research at Bayer – on your PC, tablet or smartphone. Fascinating animated sequences, videos and numerous photo galleries make science accessible and comprehensible.

Additional service for teachers: teaching materials on the iPad
A special service from Bayer AG brings teaching materials to life: our innovative materials make it easier for teachers and lecturers to integrate contemporary research work in physics, chemistry, environmental issues and bioscience into their lessons. Animations, infographics, video excursions and much more support natural science teaching. The interactive learning checks, concise educational contents and instructions for group work were developed in collaboration with educational specialists to provide real support for science teaching. The latest topic: the human immune system. This service can be downloaded as an iBook or PDF from http://www.research.bayer.com/en/teaching-materials.aspx and can also be downloaded free of charge from the Apple iBookstore. Other topics include: “Bees - Little insect, big impact” and “Breeding 3.0”.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. 

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com/. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.